A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Autor: Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G

Publikováno v: Blood Advances
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Consejo Superior de Investigaciones Científicas (CSIC)

Azacitidine-mediated hypomethylation promotes tumor cell immune recognition but may increase the expression of inhibitory immune checkpoint molecules. We conducted the first randomized phase 2 study of azacitidine plus the immune checkpoint inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::d7393970984e7951f0067f76983b56ac
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16525

A randomized phase 2 trial of azacitidine ± durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

Autor: Zeidan, Am, Boss, Iw, Beach, Cl, Copeland, Wb, Thompson, Eg, Fox, Ba, Hasle, Ve, Ogasawara, K, Cavenagh, J, Silverman, Lr, Voso, Mt, Hellmann, A, Tormo, M, O'Connor, T, Previtali, A, Rose, S, Garcia-Manero, G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3667::16f9d2ffd10784b157b49abd9bd5c948
http://hdl.handle.net/2108/293123

Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.

Autor: Danziger SA; Bristol Myers Squibb, Seattle, Washington, United States of America., McConnell M; Bristol Myers Squibb, Seattle, Washington, United States of America., Gockley J; Sage Bionetworks, Seattle, Washington, United States of America., Young MH; Sage Bionetworks, Seattle, Washington, United States of America., Rosenthal A; Cancer Research and Biostatistics, Seattle, Washington, United States of America., Schmitz F; Sage Bionetworks, Seattle, Washington, United States of America., Reiss DJ; Bristol Myers Squibb, Seattle, Washington, United States of America., Farmer P; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Alapat DV; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Singh A; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Ashby C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Bauer M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Ren Y; Bristol Myers Squibb, Seattle, Washington, United States of America., Smith K; Bristol Myers Squibb, Seattle, Washington, United States of America., Couto SS; Genmab, Princeton, New Jersey, United States., van Rhee F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Davies F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Zangari M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Petty N; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Orlowski RZ; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America., Dhodapkar MV; Winship Cancer Institute, Emory University, Atlanta, Georgia, United States of America., Copeland WB; Bristol Myers Squibb, Seattle, Washington, United States of America., Fox B; Bristol Myers Squibb, Seattle, Washington, United States of America., Hoering A; Cancer Research and Biostatistics, Seattle, Washington, United States of America., Fitch A; Bristol Myers Squibb, Seattle, Washington, United States of America., Newhall K; Sage Bionetworks, Seattle, Washington, United States of America., Barlogie B; Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America., Trotter MWB; BMS Center for Innovation and Translational Research Europe (CITRE), Seville, Spain., Hershberg RM; Sage Bionetworks, Seattle, Washington, United States of America., Walker BA; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America., Dervan AP; Sage Bionetworks, Seattle, Washington, United States of America., Ratushny AV; Bristol Myers Squibb, Seattle, Washington, United States of America., Morgan GJ; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

Publikováno v: PLoS medicine [PLoS Med] 2020 Nov 04; Vol. 17 (11), pp. e1003323. Date of Electronic Publication: 2020 Nov 04 (Print Publication: 2020).

Reaction of CO 2 with Groups 4 and 6 Transition Metal Oxide Clusters.

Autor: Flores LA; Department of Chemistry, The University of Alabama , Shelby Hall, Tuscaloosa, Alabama 35487-0336, United States., Murphy JG; Department of Chemistry, The University of Alabama , Shelby Hall, Tuscaloosa, Alabama 35487-0336, United States., Copeland WB; Department of Chemistry, The University of Alabama , Shelby Hall, Tuscaloosa, Alabama 35487-0336, United States., Dixon DA; Department of Chemistry, The University of Alabama , Shelby Hall, Tuscaloosa, Alabama 35487-0336, United States.

Publikováno v: The journal of physical chemistry. A [J Phys Chem A] 2017 Nov 16; Vol. 121 (45), pp. 8719-8727. Date of Electronic Publication: 2017 Nov 07.

Computational tools for metabolic engineering.

Autor: Copeland WB; Department of Bioengineering, University of Washington, Seattle, WA 98195-5061, USA. wcopelan@uw.edu, Bartley BA, Chandran D, Galdzicki M, Kim KH, Sleight SC, Maranas CD, Sauro HM

Publikováno v: Metabolic engineering [Metab Eng] 2012 May; Vol. 14 (3), pp. 270-80.